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Cell deathDiabetic retinopathy, a leading cause of vision loss inworking-age population, is often associatedwith inﬂammation
and apoptosis.We have previously reported that sitagliptin, a DPP-IV inhibitor, exerts beneﬁcial effects in the retina
of type 2 diabetic animals. The present study aimed to evaluatewhether sitagliptin can exert protective effects in the
retina of type 1 diabetic animals by a mechanism independent of insulin secretion and glycemia normalization.
Streptozotocin-induced diabetic rats were treated orally with sitagliptin (5 mg/kg/day) for the last twoweeks of
4 weeks of diabetes. Sitagliptin treatment did not change the weight and glucose, HbA1c or insulin levels. How-
ever, it prevented the diabetes-induced increase in DPP-IV/CD26 activity and levels in serum and retina.
Sitagliptin also prevented the increase in blood–retinal barrier (BRB) permeability and inhibited the changes in
immunoreactivity and endothelial subcellular distribution of occludin, claudin-5 and ZO-1 proteins induced by
diabetes. Furthermore, sitagliptin decreased the retinal inﬂammatory state and neuronal apoptosis.
Sitagliptin inhibited the BRB breakdown in a type 1 diabetic animal model, by a mechanism independent of nor-
malization of glycemia, by preventing changes in tight junctions (TJs) organization. Sitagliptin also exerted pro-
tective effects against inﬂammation and pro-apoptotic state in the retina of diabetic rats. Altogether, these results
suggest that sitagliptinmight be envisaged to be used to prevent or delay some of the alterations associatedwith
the development of diabetic retinopathy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetes is associatedwith the development ofmicrovascular compli-
cations, being the most common diabetic retinopathy. Chronic hypergly-
cemia leads to retinal endothelial cell dysfunction resulting in, among
other effects, pericyte loss, formation of acellular capillaries, increased
vessel permeability and leukocyte adhesion [1]. In streptozotocin-
induced diabetic mice and rats, as well as in diabetic humans, it has
been demonstrated an increase in blood–retinal barrier (BRB) permeabil-
ity, which is the hallmark of the early stages of diabetic retinopathy
progression [2–4]. Diabetes-induced vascular permeability seems to beblood–retinal barrier; DPP-IV,
GLP-1R, glucagon-like peptide-
; PFA, paraformaldehyde; STZ,
ty; ZO-1, zonula occludens-1
and Experimental Therapeutics,
ugal. Tel.: +351 239480072;
s).correlatedwith the disruption of tight junctions (TJs), which form a com-
plex network structure between the endothelial cells, comprising the
inner BRB [5,6]. It has been described that chronic hyperglycemia induces
changes in the levels and distribution of TJ proteins within the retinal
vascular endothelium, which seem to directly contribute to increased
vascular permeability [3,4,7,8]. Also, inﬂammatory mediators have been
shown to promote increased vascular permeability, leukocyte adhesion
and retinal cell death [9,10]. In fact, elevated levels of proinﬂammatory
cytokines have been detected in the vitreous of diabetic patients with
retinopathy [11] and in diabetic rat retinas with increased vascular per-
meability [12,13].
Although good glycemic control can reduce the risk for the develop-
ment of diabetic retinopathy, even in patients with good glycemic con-
trol the disease can progress to more advanced stages. Therefore, it
becomes imperative to implement new and effective therapeutic strat-
egies capable of preventing or attenuating the progression of diabetic
retinopathy, preferably during the earlier stages of the disease.
Sitagliptin, a dipeptidyl peptidase IV (DPP-IV, also known as CD26;
EC 3.4.14.5) inhibitor, has been widely used as a clinical approach for
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The inhibition of DPP-IV stabilizes the glucagon-like peptide (GLP-1),
which stimulates its receptor thus enhancing the insulin production in
response to chronic hyperglycemia. Diabetic patients without decrease
in glucose levels through diet or oral medications have been shown to
improve glycemic control with sitagliptin therapy [14]. Its clinical effec-
tiveness seemed to occur mainly through an increase in the levels of
the incretin hormone GLP-1, mediated by DPP-IV enzyme inhibition,
exerting a number of actions that improve glucose homeostasis, includ-
ing the enhancement of glucose-stimulated insulin secretion, promotion
of beta-cell proliferation and survival, and inhibition of glucagon secre-
tion [15]. DPP-IV is expressed in several cell types, including neuronal
cells and brain capillary endothelial cells [16], being also found in the
plasma and its inhibition increases GLP-1 plasma concentration [17].
Besides the insulinotropic effects of GLP-1 receptor (GLP-1R) activation
in pancreatic cells, this receptor was shown to be expressed in a wide
range of tissues, including the retina [18].
Recent studies have demonstrated beneﬁcial effects of incretin-based
therapies in the vasculature [19,20], kidney [21], heart [22] andbrain [23].
Regarding the retina, it was reported that intravitreal injection of a GLP-1
analog (Exendin-4), could reverse changes in electroretinograms, pre-
vent retinal cell death and maintain normal retinal thickness in diabetic
rats [24]. Recently, we have demonstrated that sitagliptin can exert ben-
eﬁcial and protective effects in the BRB, inhibit apoptosis and inﬂamma-
tion, and positively modulate endothelial progenitor cells in a type 2
diabetes animal model [25]. In this work, we showed, for the ﬁrst time,
that the beneﬁcial effects of DPP‐IV inhibition on diabetic retina can be
explained, at least partially, by amechanism independent of increased in-
sulin secretion. Ourﬁndings show that sitagliptin has protective effects in
the early stages of diabetic retinopathy in a type 1 diabetic animal model
independent of insulin secretion and normalization of glycemia levels, by
a mechanism involving the regulation of TJ proteins and vascular repair.
Moreover, its effects on inﬂammation and cell deathwere also addressed.
2. Material and methods
2.1. Animal model
All procedures involving animals were performed according to the
ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research and approved by the Institutional Ethics Committee of the
Faculty of Medicine of University of Coimbra for animal care and use
(Approval ID: 015-CE-2011).
MaleWistar rats (8 weeks old)were housed at approximately 22 °C,
60% relative humidity, and a 12-h light, 12-h dark cyclewasmaintained.
Throughout the study the animals had access to water and standard rat
diet (SAFE A04 Augy, France) ad libitum. Diabetes was induced with a
single intraperitoneal injection of streptozotocin (STZ, Sigma-Aldrich,
St. Louis, MO, USA; 65 mg/kg in 10 mM citrate buffer, pH 4.5). After
48 h, animalswith blood glucose levels above 13.9mMwere considered
diabetic.
After 2 weeks of diabetes induction, the animals were divided into
three groups (number of animals stated in each ﬁgure legend): controls,
diabetics and diabetics treated with 5 mg/kg/day (via oral gavage)
sitagliptin (Januvia®, MSD, Portugal) during the following 2 weeks. A
set of animals were also treated with sitagliptin, and the results obtained
for the several measured parameters described in this section were sim-
ilar to those obtainedwith non-treated control animals (data not shown).
2.2. Measurement of serum glucose, insulin and glycosylated hemoglobin
(HbA1c) levels
Ratswere anesthetizedwith an intraperitoneal injection of a cocktail
(2 mg/kg): 2:1 50 mg/mL ketamine solution in 2.5% chlorpromazine,
and blood samples from the jugular vein were collected. Serum glucose
and insulin levels weremeasured using commercial kits (Sigma-AldrichandMercodia, Uppsala, Sweden, respectively) andHbA1c levels by using
the DCA 2000+ analyzer (Bayer Diagnostics, Barcelona, Spain), accord-
ing to the instructions of the manufacturer.
2.3. Western blot analysis
Retinal extracts were prepared as previously described [25]. For the
Western blot analysis, 40 μg of protein from the retinal extracts or
100 μg from serum samples were loaded per lane, separated by electro-
phoresis on a SDS 7.5 or 10% polyacrylamide gel and transferred
to polyvinylidene diﬂuoride membranes (Boehringer Mannheim,
Mannheim, Germany). Membranes were probed with rabbit polyclonal
anti-DPP-IV/CD26 (1:4000) from Abcam (Cambridge, UK), rabbit poly-
clonal anti-intercellular adhesion molecule-1 (ICAM-1; 1:200) and
rabbit polyclonal anti-Bax (1:200) from Santa Cruz Biotechnology
(Santa Cruz, CA, USA), goat polyclonal anti-serum albumin (1:5000)
from Bethyl Laboratories, Inc. (Montgomery, TX, USA) and mouse
monoclonal anti-β-actin (1:10,000) antibody from Sigma-Aldrich. After
washing, the membranes were probed with a secondary anti-goat,
anti-rabbit or anti-mouse IgG-HRP-linked antibody (1:10,000; Bio-Rad,
Hercules, CA, USA) for 1 h at room temperature. Immunoreactive
bands were detected by an enhanced chemiluminescence (ECL) sub-
strate using an imaging system (VersaDoc 4000 MP, Bio-Rad).
2.4. DPP-IV enzyme assay in serum
To measure the activity of DPP-IV in the serum, a ﬂuorometric assay
was employed, using H-Gly-Pro-AMC.HBr (BACHEM, Bubendorf,
Switzerland). Gly-Pro-AMC is cleaved by DPP-IV to release the ﬂuores-
cent aminomethylcoumarin (AMC). Brieﬂy, 20 μL of serum sample
was mixed with the assay buffer (50 mM glycine, 1 mM EDTA, pH 8.7)
at room temperature. The reaction was initiated by the addition of the
ﬂuorogenic substrate to a ﬁnal concentration of 200 μM. The ﬁnal reac-
tion volume for eachwell was 100 μL. Liberation of AMCwasmonitored,
using an excitation wavelength of 360 nm and an emission wavelength
of 460 nm (microplate reader Synergy HT, BioTek, Winooski, VT, USA),
every 5 min for a total of 60 min.
For comparison of DPP-IV activity between samples, data was plot-
ted as Relative Fluorescence Units versus time for each sample. The
time range over which the reaction was linear was determined. A
trend line for these data pointswas obtained and the slopes determined.
2.5. Immunohistochemistry in retinal sections
Retinal sections (10 μm) were ﬁxed in cold acetone for 10 min. The
sections were then washed with PBS, permeabilized for 30 min with
0.25% Tx-100 in PBS with 0.02% BSA (PBS/BSA) and blocked with 10%
normal goat serum or 5% BSA before incubation overnight at 4 °C with
primary antibodies: goat polyclonal anti-IL-1β (1:100; R&D Systems,
Minneapolis, MN, USA), rabbit polyclonal anti-DPP-IV/CD26 (1:200,
Abcam) and rabbit polyclonal anti-Bax (1:50, Santa Cruz Biotechnology).
Sections were then rinsed with PBS and incubated with DAPI for nuclear
staining and the secondary ﬂuorescent antibodies for 1 h at room
temperature.
Anti-DPP-IV/CD26 immunostaining samples were imaged using a
confocal microscope (LSM 710, Carl Zeiss, Gottingen, Germany). Anti-
IL-1β and anti-Bax immunostaining samples were imaged using a
ﬂuorescence microscope (Leica DFC350 FX, Leica Microsystems, Ban-
nockburn, IL, USA). Fluorescence intensity of 5 ﬁelds per retinal section
from four animals of each group was quantiﬁed by two independent
observers in a masked fashion.
2.6. Measurement of BRB permeability
Blood–retinal barrier permeability was quantiﬁed using the Evans
blue dye, which binds irreversibly to serum albumin, according to the
Table 1
Bodyweight, blood glucose, glycated hemoglobin and insulin levels in control and diabetic
Wistar rats nontreated or treated with 5 mg/kg/day sitagliptin for 2 weeks.
Control Diabetic Diabetic + Sita
Body weight (g) 319.00 ± 7.26 229.30 ± 5.37a 230.70 ± 5.65
Glucose (mM) 9.24 ± 0.60 40.22 ± 3.07a 41.02 ± 3.32
HbA1c (%) 3.83 ± 0.06 9.68 ± 0.09a 9.16 ± 0.25
Insulin (pM) 584.64 ± 76.56 19.14 ± 3.48a 22.62 ± 6.96
Data are expressed as mean ± SEM of 10–12 animals per group.
a P b 0.001 vs. control rats. ANOVA followed by Bonferroni's post hoc test.
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thesia, the rats were administered Evans blue (100 mg/kg; Sigma-
Aldrich) via tail vein. After 2 h, the animals were perfused with
citrate-buffered (0.05 M, pH 4.2) 1% paraformaldehyde (PFA) for
2 min. The eyes were enucleated and the retinas isolated andweighted.
The Evans blue dye was extracted from the retinas with formamide for
18 h at 70 °C. The extract was then centrifuged at 70,000 g for 45min at
4 °C. The absorbance of the supernatant was measured at 620 nm
(maximum absorbance) and 720 nm (minimum absorbance). The
concentration of the dye in the extracts was calculated from a stan-
dard curve of Evans blue in formamide and normalized to the retina
wet weight.
2.7. Visualization of retinal vessel leakage
Evans blue dye was also used to qualitatively assess the retinal vas-
cular leakage. The Evans blue (100 mg/kg in PBS) was administered via
tail vein to the anesthetized rats. After 30min, the eyeswere enucleated
and immediately immersed in 2% PFA for 2 h. The retinas were isolated
and ﬂat-mounted with the vitreous side up for visualization under a
ﬂuorescence microscope (Leica DFC350 FX, Leica Microsystems). All of
the images were acquired in a masked fashion.
2.8. Whole-mount staining
Retina whole-mounts were prepared according to the procedure
previously described by our group [3]. The retina whole-mounts were
immunostained with mouse monoclonal anti-occludin (1:100), rabbit
polyclonal anti-claudin-5 (1:100), and rabbit polyclonal anti-zonula oc-
cludens‐1 (ZO-1; 1:100) from Zymed Laboratories (San Francisco, CA,
USA). After washing, the retinas were incubated with the secondary
antibody Alexa Fluor 488-conjugated goat anti-rabbit IgG or Alexa
Fluor 568-conjugated goat anti-mouse IgG (Life Technologies, Pais-
ley, UK) and then mounted with the vitreous side up for visualiza-
tion under a confocal microscope (LSM 510, Carl Zeiss). From each
retina, 10 images were used to analyze occludin, claudin-5 and ZO-
immunoreactivity. The ﬂuorescence intensity for the three tight
junction proteins was measured in 30–40 retinal vessels of each ex-
perimental group.
2.9. Elisa
Retinal tissue was homogenized in 20 mM imidazole HCl (pH 6.8),
100 mM KCl 1 mM MgCl2, 1% Triton X-100, 1 mM EGTA, 1 mM EDTA,
supplementedwith 10mMNaF, 1mMNa3VO4 and 1×protease inhibitor
cocktail (Roche, Indianapolis, IN, USA). The samples were centrifuged at
4 °C for 5 min at 10,000 g, and IL-1β was assayed in the supernatant
using an ELISA kit (Peprotech, Rocky Hill, NJ, USA), according to the
manufacturer's instructions.
2.10. Apoptosis assay
Apoptotic cell death was detected by TUNEL using the DeadEnd
Fluorometric TUNEL System (Promega, Madison, WI, USA) and
degenerating neurons were assessed by Fluoro-Jade B staining
(Chemicon, Temecula, CA, USA), according to the instructions of the
manufacturers. Slides were then analyzed under a confocal microscope
(LSM 710, Carl Zeiss).
2.11. Statistical analysis
Data are expressed as mean ± SEM. Signiﬁcance was determined
using ANOVA followed by Bonferroni's post hoc test (GraphPad Prism
5.0 software, La Jolla, CA, USA), as indicated in ﬁgure legends. Values
of P b 0.05 were considered statistically signiﬁcant.3. Results
3.1. Sitagliptin has no effect on body weight, and blood glucose, HbA1c or
insulin levels in diabetic animals
Diabetic animals presented impaired gain weight throughout the
study, with 29% (P b 0.001) less bodyweight than age-matched control
animals at 12 weeks of age (Table 1).
The average blood glucose levels of diabetic animals (40.22 ±
3.07 mM; P b 0.001) were signiﬁcantly higher than those of control an-
imals (9.24 ± 0.60 mM). Accordingly, diabetic animals also presented
increased levels of HbA1c (9.68 ± 0.09%; P b 0.001) when compared
to controls (3.83 ± 0.06%) (Table 1).
As expected, STZ-induced diabetes reduced signiﬁcantly the insulin
levels in serum when compared to control animals (19.14 ± 3.48 pM
and 584.64 ± 76.56 pM, respectively; P b 0.001) (Table 1).
Treatment with sitagliptin during the last 2 weeks of diabetes did
not affect signiﬁcantly bodyweight (230.70± 5.65 g), and blood glu-
cose (41.02 ± 3.32 mM), HbA1c (9.16 ± 0.25%) or insulin levels
(22.62 ± 6.96 pM) when compared to untreated diabetic animals
(Table 1).
3.2. Sitagliptin decreases the activity and protein levels of DPP-IV in diabetic
animals
To investigate the effect of sitagliptin on DPP-IV, its activity and pro-
tein levels were evaluated in the serum, and in the retina, the protein
levels and distributionwere assessed byWestern blotting and immuno-
histochemistry, respectively.
The activity of soluble DPP-IV was signiﬁcantly increased in the
serum of diabetic animals (129.9± 4.3% of control; P b 0.001). In diabetic
animals, sitagliptin decreased the activity of DPP-IV to 39.3 ± 4.521% of
control (P b 0.001), corresponding to a 70% decrease when compared to
untreated diabetic animals (Fig. 1A).
The protein levels of soluble DPP-IV were assessed in the serum by
Western blottingusing a speciﬁc antibody against DPP-IV/CD26. Diabet-
ic animals presented increased DPP-IV levels (182.9± 24.7% of control;
P b 0.01) (Fig. 1B). Sitagliptin signiﬁcantly reduced DPP-IV protein
levels in the serum of diabetic animals (101.7 ± 14.5% of control;
P b 0.01), compared to untreated animals (Fig. 1B).
DPP-IV protein levels were also assessed in the retina byWestern
blotting. Diabetes led to increased DPP-IV levels in total retinal ex-
tracts (128.7 ± 10.5% of control; P b 0.05) (Fig. 1C). The administra-
tion of sitagliptin to diabetic rats prevented the increase in DPP-IV
protein levels in the retina, compared to diabetic animals without
treatment (98.8 ± 8.5% of control; P b 0.05) (Fig. 1C). Since the in-
crease in CD26 immunostaining could be due to increased leakage
into the retinal parenchyma of diabetic animals, a Western blot to
detect serum albumin was performed, with no staining detected
(Fig. 1C). Immunohistochemistry experiments performed in retinal
frozen sections conﬁrmed these results (Fig. 1D, E). Diabetes promoted
a signiﬁcant increase in DPP-IV immunoreactivity (119.6 ± 2.2% of
control; P b 0.001), particularly in the ganglion cell layer. Treatment
with sitagliptin markedly decreased the immunoreactivity for DPP-IV
Fig. 1. Sitagliptin prevents the upregulation of DPP-IV activity and content induced by diabetes. (A) DPP-IV activity was determined in the serum using the ﬂuorogenic substrate Gly-Pro-
AMC. The protein levels of DPP-IV/CD26 (110–120 kDa) and serum albumin (65 kDa) were assessed byWestern blotting in serum samples (B) and retinal lysates (C). TheWestern blots
presented are representative of each group of animals. Data are presented as percentage of control and represent themean± SEM of 7–8 animals. (D) Representative confocal images for
each group of animals, showing DPP-IV/CD26 immunoreactivity (green) and nuclear staining with DAPI (blue) in retinal sections. Magniﬁcation 400×. Bar: 20 μm. (E) Quantiﬁcation of
ﬂuorescence intensity for DPP-IV/CD26 immunoreactivity in retinal frozen sections (10 μm). Data are presented as percentage of control and represent the mean ± SEM of 5 ﬁelds per
section from 4 animals; ***P b 0.001, **P b 0.01, *P b 0.05 vs. control rat; #P b 0.05, ##P b 0.01, ###P b 0.001 vs. diabetic rats. ANOVA followed by Bonferroni's post hoc test. Legend:
GCL — ganglion cell layer; IPL — inner plexiform layer; INL — inner nuclear layer; ONL — outer nuclear layer; PRL — photoreceptor layer.
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(Fig. 1D, E).
3.3. Sitagliptin prevents the increase in BRB permeability induced
by diabetes
The breakdown of the BRB induced by diabetes was assessed by
Evans blue extravasation from retinal vessels. As a ﬁrst approach, the
retinal blood vessel integrity was analyzed in ﬂat mount retinas. Evans
blue was shown to be conﬁned to the retinal blood vessels, without
any leakage occurring, in control rats (Fig. 2A). After 1 month of diabe-
tes, the dye was shown to leak from the capillaries and larger vessels to
the surrounding tissue. The administration of sitagliptin to diabetic an-
imals was able to prevent this effect (Fig. 2A). The quantitative measure
of Evans blue dye, from the retinal tissue, conﬁrmed the data obtained
by ﬂuorescence microscopy. Diabetes increased the BRB permeability
in diabetic rats (15.8 ± 1.4 μg Evans blue per g wet weight retina;
P b 0.01) when compared to control rats (7.2 ± 1.0 μg Evans blue
per g wet weight retina) (Fig. 2B). Treatment with sitagliptin signiﬁ-
cantly prevented BRB breakdown in diabetic rats (9.7 ± 1.7 μg Evans
blue per g wet weight retina; P b 0.05) when compared to untreated
diabetic animals (Fig. 2B).3.4. Sitagliptin prevents the alterations in the distribution of TJ proteins in
retinal vessels induced by diabetes
In order to establish a correlation between the effects observed on
the BRB permeability and TJ organization, whole retinas were immuno-
stained for the three main constituents of these junctions, zonula
occludens (ZO)-1, occludin and claudin-5. In control animals, the
immunoreactivity for all three proteins was preferentially localized at
the plasma membrane of retinal endothelial cells. In some retinal
vessels of diabetic animals, there were pronounced alterations in
the subcellular distribution of the three TJ proteins. A quantitative
analysis revealed that there was a signiﬁcant decrease in ZO-1
(58.8 ± 10.7% of control; P b 0.05) and claudin-5 (45.4 ± 3.6% of
control; P b 0.001) immunoreactivity at endothelial cell borders, as
well as intracellular accumulation of occludin in retinal vascular
endothelial cells when compared to control animals (Fig. 2C, D).
Treatment with sitagliptin was able to signiﬁcantly prevent the de-
crease in claudin-5 (91.8 ± 4.3% of control; P b 0.001) and occludin
(106.9 ± 11.2% of control; P b 0.05) immunoreactivity at the cell
membranes, as well as the redistribution and intracellular accumula-
tion of occludin in the endothelial retinal cells. Although a recovery
of ZO-1 staining at the cell borders was noticed in the retinas of
Fig. 2. Sitagliptin protects against the increase in BRB permeability and tight junction disassembly triggered by diabetes. (A) Representative images, from 3 animals per group, showing
Evans blue ﬂuorescence in the retina. Evans blue, which binds to blood albumin, allows the detection of leakage sites (arrows) in the retinal vessels. Magniﬁcation: 100×. (B) Quantitative
measurement of BRB permeability by quantiﬁcation of extravasated Evans blue to retinal parenchyma. Data are presented as μg of Evans blue per retinawet weight (g) and represent the
mean ± SEM of 5–6 animals. (C) Sitagliptin prevents the decrease in ZO-1 and claudin-5 immunoreactivity, and the redistribution and accumulation of occludin in rat retinal vessels in-
duced by diabetes. Whole mount preparations of the retinas were imaged by ﬂuorescence confocal microscopy, and images are representative of each group of animals. Magniﬁcation
400×. Bar: 20 μm. (D) Quantiﬁcation of cell border immunostaining for the tight junction proteins (ZO-1, occludin and claudin-5). Data are presented as percentage of control and represent
the mean ± SEM of at least 10 ﬁelds per retina from 4 animals. *P b 0.05, **P b 0.01 vs. control rats; #P b 0.05, ###P b 0.001 vs. diabetic rats. ANOVA followed by Bonferroni's post hoc test.
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was reached when comparing to ZO-1 staining in the retinas of diabetic
animals (Fig. 2C, D).
3.5. Sitagliptin is able to decrease inﬂammation in the retina of diabetic
animals
Inﬂammation has been implicated in the pathogenesis of diabetic
retinopathy, and IL-1β, a proinﬂammatory cytokine, has been correlated
with BRB breakdown [13,26]. As expected, the results obtained by
immunohistochemistry revealed that the retinas of diabetic animals
presented an overall increase in IL-1β (191.8 ± 7.1% of control;
P b 0.001) (Fig. 3A, B) immunoreactivity. Treatment with sitagliptin
signiﬁcantly decreased the immunoreactivity for IL-1β (117.4 ± 3.4%
of control; P b 0.001) in the retinas of diabetic animals, particularly in
the ganglion cell layer and inner plexiform layer (Fig. 3A, B). As shown
in Fig. 3C, IL-1β levels in the retina of diabetic animals were higher
(2550 ± 80.66 pg/mL) compared to control (1849 ± 151.2 pg/mL), as
assessed by ELISA. Treatment with sitagliptin was able to prevent thisincrease (1981 ± 138.2 pg/mL; P b 0.05), when compared to untreated
animals (Fig. 3C).
As the inﬂammatory process develops, the increase of local cytokine
levels will promote the leukocyte adhesion to retinal vessels mediated
by ICAM-1, which is expressed by endothelial cells [27]. ICAM-1 protein
levels were signiﬁcantly increased in the diabetic retinas (138.2 ± 9.6%
of control; P b 0.05) (Fig. 3D). Sitagliptin treatment prevented the in-
crease of this adhesion molecule induced by diabetes (102.4 ± 6.8% of
control; P b 0.01) (Fig. 3D).
3.6. Sitagliptin prevents neuronal cell death induced by diabetes
The death of pericytes and acellular capillary formation are common
features of the early stages of diabetic retinopathy and impaired angio-
genic response to increased vascular permeability, may contribute to
the breakdown of BRB [28]. Moreover, it has been shown that transloca-
tion of Bax, a pro-apoptotic protein, into the mitochondria triggers a
caspase-dependent apoptosis in retinal cells exposed to chronic hyper-
glycemia [29].
Fig. 3. Sitagliptin inhibits the increase in IL-1β and ICAM-1 levels in the retina of diabetic animals. Representative ﬂuorescence images for each group of animals, showing IL-1β
(A) immunoreactivity (green) and nuclear stainingwith DAPI (blue) in retinal sections (10 μm).Magniﬁcation 200×. Bar: 40 μm. Legend: GCL— ganglion cell layer; IPL— inner plexiform
layer; INL — inner nuclear layer; OPL— outer plexiform layer; ONL — outer nuclear layer; PRL — photoreceptor layer; RPE — retinal pigment epithelium. Quantiﬁcation of ﬂuorescence
intensity for IL-1β (B) immunoreactivity in retinal sections. Data are presented as percentage of control and represent the mean ± SEM of 5 ﬁelds per section from 4 animals per
group. The levels of IL-1β were quantiﬁed in the supernatant of total retina homogenates, by ELISA (C). Data are presented as pg/mL of IL-1β and represent the mean ± SEM of 5–6
animals. The protein levels of ICAM-1 (110 kDa) were assessed by Western blotting in total retinal extracts (D). The Western blot presented is representative of each group of animals.
Data are presented as percentage of control and represent the mean ± SEM of 7–8 animals. ***P b 0.001, **P b 0.01, *P b 0.05 vs. control rats; ###P b 0.001, ##P b 0.01, #P b 0.05 vs.
diabetic rats. ANOVA followed by Bonferroni's post hoc test.
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protein levels was detected in the retinas of diabetic rats, when com-
pared to the control animals (Fig. 4A). The administration of sitagliptin
signiﬁcantly decreased the pro-apoptotic state (90.4 ± 5.8% of control;
P b 0.01) induced by diabetes (Fig. 4A). These observations were
conﬁrmed by immunohistochemistry experiments. Diabetes induced
an increase in Bax immunoreactivity in the retina (137.1 ± 7.2% of
control; P b 0.001), especially at the plexiform and photoreceptor
layers, indicating a pro-apoptotic state. Oral treatment with sitagliptin
for 2 weeks was able to prevent the increase in Bax immunoreactivity
in the diabetic retinas (114.8 ± 5.2% of control; P b 0.05) comparing
to untreated animals (Fig. 4B, C). These results were conﬁrmed by
TUNEL assay. The number of TUNEL-positive cells (cells undergoing ap-
optosis) was increased in the diabetic retinas (2.3± 0.4 TUNEL-positive
cells per 100 μm horizontal length; P b 0.001), when compared to con-
trol animals (0.3 ± 0.1 TUNEL-positive cells per 100 μm horizontal
length). Besides the TUNEL-positive cells at the outer nuclear layer,
we also observed TUNEL-positive staining at the ganglion cell layer
in some of the retinal sections analyzed (Fig. 4D). Treatment with
sitagliptin signiﬁcantly decreased the number of TUNEL-positive cells
in the diabetic retinas (1.2 ± 0.2 TUNEL-positive cells per 100 μm hori-
zontal length; P b 0.05) (Fig. 4D, E).
To further investigate the potential protective effects of sitagliptin
against retinal cell death, retinal sections were stained with Fluoro-
Jade B, which is a well-established marker of degenerating neurons in
the brain and retina [30,31]. In control retinas, we could not detect
any staining indicative of cell death (Fig. 4F). In diabetic retinas,degenerating cell bodies were observed mainly in the ganglion cell
and inner nuclear layers (arrows). Furthermore, some astroglial pro-
cesses were also stained, extending from the ganglion cell layer to the
inner plexiform layer (Fig. 4F). In the retinas of diabetic animals treated
with sitagliptin, no speciﬁc staining of cell bodies indicative of cell death
was found (Fig. 4F).
4. Discusssion
The present study is the ﬁrst providing evidence that DPP-IV inhi-
bition with sitagliptin has protective effects in the retina of diabetic
animals by a mechanism independent of enhanced insulin secretion.
Most research on sitagliptin has been focused on type 2 diabetes
with normalization of blood glucose [17,25,32,33]. In this work,
we show that sitagliptin was able to prevent several alterations oc-
curring in the retina in a type 1 diabetes animal model, during the
early stages of the disease. Sitagliptin prevented BRB breakdown, TJ
complexes disassembly/disorganization, inﬂammation, retinal cell
apoptosis, and the impairedmobilization and adhesion ability of circulat-
ing cells with vasculogenic potential, despite continued hyperglycemia
and hypoinsulinemia. These results indicate that sitagliptin has direct ef-
fects on the retina that are independent of its antihyperglycemic effects.
Elevated serum DPP-IV activity has been described in both type 2
and type 1 diabetic patients [34,35]. We observed an increased serum
DPP-IV activity after onemonth of diabetes induced by STZ (type 1 dia-
betes). In other study, using the same animal model, DPP-IV activity in
the plasma is increased 1 week after STZ injection and treatment with
Fig. 4. Sitagliptin prevents neuronal cell death induced by diabetes in the retina. (A) The protein levels of Bax were assessed byWestern blotting in retinal lysates. TheWestern blots pre-
sented are representative of each experimental group. Data are presented as percentage of control and represent themean± SEM of 7–8 animals. (B) Representative ﬂuorescence images
of Bax immunoreactivity (green) and nuclear staining with DAPI (blue) in 10 μm retina sections. Magniﬁcation 200×. Bar: 40 μm. (C) Quantiﬁcation of ﬂuorescence intensity of Bax im-
munoreactivity in retinal frozen sections. Data are presented as percentage of control and represent the mean ± SEM of 5 ﬁelds per section from 4 animals; (D) Representative confocal
images for each group of animals showing TUNEL-positive cells (green, arrows) and nuclear counterstainingwith DAPI (blue) in retinal sections. Magniﬁcation 400×. Bar: 20 μm. Legend:
GCL— ganglion cell layer; IPL— inner plexiform layer; INL— inner nuclear layer; ONL— outer nuclear layer; PRL— photoreceptor layer. (E)Quantiﬁcation of the number of TUNEL-positive
cells in retinal sections. Data are presented as number of TUNEL-positive cells per 100 μmhorizontal length and represent themean± SEMof 5 ﬁelds per section from4 animals; *P b 0.05,
***P b 0.001 vs. control rats; #P b 0.05, ##P b 0.01 vs. diabetic rats. ANOVA followed by Bonferroni's post hoc test. (F) Representative confocal images of each experimental group showing
degenerating cell bodies (arrows) stained with Fluoro-Jade B. Magniﬁcation 400×. Bar: 20 μm. Legend: GCL— ganglion cell layer; IPL— inner plexiform layer; INL— inner nuclear layer;
ONL — outer nuclear layer; PRL — photoreceptor layer.
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and concomitantly increased levels of active plasma GLP-1 levels [36].
In our study, 2 weeks of treatment with sitagliptin was able to inhibit
by 70% the activity of DPP-IV in the serumof diabetic animals, comparedto untreated animals. Furthermore, we observed a positive correlation
between serum DPP-IV activity and its serum protein levels in diabetic
animals. The same correlation has also been described for type 2 diabe-
tes and other diseases, like rheumatoid arthritis [32,37], suggesting that
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levels. Indeed, we found that the inhibition of DPP-IV activity also pro-
moted a decrease in its serum levels. In the retina, sitagliptin was also
able to prevent the increase in DPP-IV levels induced by diabetes. It re-
mains to be clariﬁed if the positive correlation between activity and
DPP-IV levels is maintained for DPP-IV in the retina.
Increased retinal vascular permeability, which may cause macular
edema, is a well-established consequence of diabetes, and is one of
the ﬁrst detectable signs of the development of diabetic retinopathy
[2]. In our animalmodel of diabetes, increased BRBpermeabilitywas ob-
served one month after STZ injection. Consistently, it has been shown
that within 1 week after STZ induction of diabetes, diabetic rodents
demonstrate increased BRB permeability to high-molecular weight
molecules [38]. In the present study, sitagliptin effectively inhibited
the increased permeability of retinal vessels induced by diabetes.
It iswell established that diabetes-induced BRB breakdown ismainly
due to TJ complex disassembly [3,4,7,8]. We showed that sitagliptin
protected the barrier function by preventing the downregulation or
subcellular redistribution of the TJ proteins claudin-5, occludin, and
ZO-1. Sitagliptin prevented the decreased ZO-1 and claudin-5 immuno-
staining in retinal endothelial cell plasmamembrane, and the intracellu-
lar accumulation of occludin induced by diabetes. Consistently, we and
others previously observed a reduction in occludin content and a sub-
cellular redistribution, due to translocation from the plasmamembrane
to intracellular compartments of endothelial cells in response to diabe-
tes, with concomitant increased vascular permeability [4,8,25,39]. These
changes appear to be correlated with increased occludin phosphoryla-
tion, which may target this protein to degradation [7] and also alter its
interaction with ZO-1 and ZO-2, compromising the integrity of the TJ
[40]. ZO-1 decreased levels and changes in its localization and phos-
phorylation state also appear to be associatedwith increased endotheli-
al permeability [3,4,7]. Moreover, a decrease in the protein levels of
claudin-5 has also been correlated with increased vascular permeability
induced by diabetes [4].
Several studies have implicated a chronic low-grade inﬂammation in
the pathogenesis of diabetic retinopathy. Elevated levels of proinﬂam-
matory cytokines and adhesion molecules have been detected in the
vitreous of diabetic patients with diabetic retinopathy and in diabetic
rat retinas [11,12,25,41]. Moreover, increased levels of both IL-1β and
ICAM-1 have been correlatedwith increased retinal vascular permeabil-
ity [4,10,13]. Our results are consistent with these ﬁndings, since we
observed increased IL-1β and ICAM-1 levels in the diabetic retinas,
along with an increase in BRB permeability. Sitagliptin seems to have
an anti-inﬂammatory effect, because it prevented the increase of both
inﬂammatory mediators in the retinas of diabetic animals, which
might contribute for the prevention of the BRB breakdown. In fact, we
and others have previously reported that this DPP-IV inhibitor de-
creases IL-1β levels in the serum, pancreas and retina of Zucker diabetic
fatty (ZDF) rats [25,33,42], as well as in the serum of type 2 diabetic
patients [43].
Studies have shown that both hyperglycemia and IL-1β are able to
activate nuclear factor-κB (NF-κB) leading to the upregulation of cell
surface expression of adhesive proteins, namely ICAM-1, in endothelial
cells [44,45] A recent in vitro study also showed that sitagliptin pro-
motes a dose dependent inhibition of tumor necrosis factor induction
of ICAM-1, through an inhibition of NF-κB expression, and that this ef-
fect was both GLP-1-dependent and independent [46]. Furthermore,
capillary occlusion by inﬂammatory mediators has been shown to con-
tribute to the formation of acellular capillarieswhich are considered one
of the early markers of diabetic retinopathy, leading to the progression
of cell death and ischemia [47]. Thus, by inhibiting the inﬂammatory
processes, sitagliptin could have cytoprotective effects and prevent
some of the vascular alterations induced by diabetes.
It has been largely demonstrated that chronic hyperglycemia and in-
ﬂammation can lead to the activation of cell death pathways in vascular
and neuronal cells in diabetic retinopathy [48]. The present resultsindicate that diabetes increased DNA fragmentation as visualized by
TUNEL labeling and increased levels of the pro-apoptotic protein Bax.
In the majority of the previous studies, the quantiﬁcation of TUNEL-
positive cells was performed in retinal whole mounts, and the relative
changes in the number of TUNEL-positive cells between diabetic retinas
and control are about 8–9 fold [49,50]. Similar to those reports, our data
showed an 8 fold-increase in the number of TUNEL-positive cells in the
retinas of diabetic animals when compared to control. The apoptotic
cells were detected in both outer and inner layers, mainly at the outer
nuclear and ganglion cell layers in diabetic retinas. Although apoptotic
cells and reduction of layer thickness have been detected in the outer
nuclear layer [24,51], the majority of the studies claim that the most
prevalent alterations occurring after 1 month of STZ-induced diabetes
affect primarily the ganglion cell layer and inner nuclear layer [49,50].
It has been claimed that neuronal cell death can occur early in the
retinas of diabetic animals, but this is still a controversial issue, namely
regarding how early neuronal death can occur and which cell types can
be mainly affected.
Additionally, we found that diabetic retinas presented an increased
number of degenerative neurons, positively stained for Fluoro-Jade
B. Fluoro-Jade appears to be a more ubiquitous labeling agent than
was originally described. Indeed, a non-speciﬁc staining in astroglial
processes was also observed, but only in diabetic retinas, indicating
that Fluoro-Jade can stain reactive glial cells, as already described
by others [31,52]. Nonetheless, reactive astroglial staining appeared
to be decreased in the retinas of diabetic animals treated with
sitagliptin.
We have previously reported, in ZDF rats, that sitagliptin reduced
the pro-apoptotic state and cell death in the retina [25]. Similarly,
in the present study, using a type 1 diabetes animal model, we found
that sitagliptin was able to prevent the upregulation of the pro-
apoptotic protein Bax, the increase in the number of TUNEL-positive
cells and degenerating neuronal cells, suggesting that the inhibition of
DPP-IV induces neuroprotective effects in the diabetic retinas.
Furthermore, it was described that intravitreal injection of exendin-
4 (a GLP-1 analog), in STZ-induced diabetic animals, could prevent the
reduction in retinal thickness and cell loss, especially in the outer nucle-
ar layer [24]. This indicates that the anti-apoptotic effects observed in
our model might be mediated through the activation of GLP-1R present
in the retina, since sitagliptin stabilizes GLP-1. In fact, it has been
described that activation of incretin receptors in pancreatic β-cells can
promote resistance to apoptosis through the activation of several path-
ways leading to the inhibition of caspase-3, by increasing the expression
of Bcl-2 and decreasing the expression of Bax [53,54]. Moreover, recent
studies in rodents have also provided evidence of neuroprotective
effects of GLP-1 in the brain [55].
Although it remains to be clariﬁedwhether it is vascular or neuronal
dysfunction that appears ﬁrst in the development of diabetic retinopa-
thy, there is no doubt that the neurovascular unit homeostasis is crucial
to the structural and functional integrity of the retina. So, it is desirable
to prevent or slow down both the neuronal and vascular damages, as a
result of prolonged hyperglycemia.
Since the biological activity of a large number of chemokines,
adipokines, neuropeptides, and incretins is altered by DPP-IV, the inhi-
bition of this enzyme might have multiple pleiotropic effects. Taking
that into account, future studies are required to unravel the molecular
mechanisms behind the protective effects of sitagliptin in the diabetic
retina, and also to establish whether these effects are GLP-1 dependent
or independent.
In the present report, we have found that sitagliptin prevents
BRB breakdown and TJ disassembly, has anti-inﬂammatory and anti-
apoptotic effects. Thus, for the ﬁrst time, we provide evidence that
sitagliptin can have protective effects in the diabetic retina by a mecha-
nism independent of increased insulin secretion. Further studies are
warranted in order to better understand the molecular mechanisms
behind the observed beneﬁcial effects, so that sitagliptin could be
1462 A. Gonçalves et al. / Biochimica et Biophysica Acta 1842 (2014) 1454–1463envisaged as a strong candidate for further consideration as a therapeu-
tic drug in reducing the retinal complications of diabetes.
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